Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
iShares MSCI Brazil ETF USD Acc
CSBR | US
5.72
USD-0.12
-1.97%
CSBR | US
About iShares MSCI Brazil ETF USD Acc
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/07/2024
As of date
02/06/2026
Close
5.72
Open
5.85
High
5.85
Low
5.66
Champions Oncology Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company through its Tumorgraft Technology Platform provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics a software platform and data tool that contains comprehensive information derived from research services and clinical studies and sold on an annual subscriptions basis. The company markets its products through internet word of mouth and sales force to patients and physicians. The company was formerly known as Champions Biotechnology Inc. and changed its name to Champions Oncology Inc. in April 2011. Champions Oncology Inc. was incorporated in 1985 and is headquartered in Hackensack New Jersey.
View LessCSBR | US
Risk
29.4
Sharpe
-0.11
Luna's Score
49/100
Recommendation
Hold
Luna says (CSBR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
18.4%1 month
29.4%3 months
42.9%6 months
58.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
22.88
Price to book
6.77
Debt to equity
-21.41
Debt to assets
0.29
Ent. to EBITDA
26.26
Ent. to rev.
1.24
PEG
-
Other Fundamentals
EBITDA
-1.17M
MarketCap
77.82M
MarketCap(USD)
77.82M
Div. yield
-
Op. margin
9.45
Erngs. growth
-28.60
Rev. growth
11.90
Ret. on equity
-432.46
Short ratio
1.50
Short perc.
3.96
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.50
Range1M
0.73
Range3M
0.89
Volumes: Market Activity
Rel. volume
0.32
Price X volume
20.88K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 26.26 | - | Expensive |
| Ent. to Revenue | 1.24 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.77 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 42.88 | - | Lower Risk |
| Debt to Equity | -21.41 | -1.23 | Cheaper |
| Debt to Assets | 0.29 | 0.25 | Par |
| Market Cap | 77.82M | - | Emerging |
